nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—Hepatic function abnormal—Imiquimod—skin cancer	0.00753	0.00753	CcSEcCtD
Deferoxamine—Swelling—Imiquimod—skin cancer	0.00746	0.00746	CcSEcCtD
Deferoxamine—Muscle spasms—Vismodegib—skin cancer	0.00724	0.00724	CcSEcCtD
Deferoxamine—Scotoma—Temozolomide—skin cancer	0.00716	0.00716	CcSEcCtD
Deferoxamine—Eosinophilia—Vemurafenib—skin cancer	0.00661	0.00661	CcSEcCtD
Deferoxamine—Arthralgia—Vismodegib—skin cancer	0.00641	0.00641	CcSEcCtD
Deferoxamine—Myalgia—Vismodegib—skin cancer	0.00641	0.00641	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00636	0.00636	CcSEcCtD
Deferoxamine—Nervous system disorder—Vismodegib—skin cancer	0.00602	0.00602	CcSEcCtD
Deferoxamine—Skin disorder—Vismodegib—skin cancer	0.00597	0.00597	CcSEcCtD
Deferoxamine—Infestation NOS—Vemurafenib—skin cancer	0.00595	0.00595	CcSEcCtD
Deferoxamine—Infestation—Vemurafenib—skin cancer	0.00595	0.00595	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Vemurafenib—skin cancer	0.00583	0.00583	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vismodegib—skin cancer	0.0056	0.0056	CcSEcCtD
Deferoxamine—Dysuria—Imiquimod—skin cancer	0.00532	0.00532	CcSEcCtD
Deferoxamine—Liver disorder—Docetaxel—skin cancer	0.0053	0.0053	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vismodegib—skin cancer	0.0053	0.0053	CcSEcCtD
Deferoxamine—Pain—Vismodegib—skin cancer	0.00525	0.00525	CcSEcCtD
Deferoxamine—Connective tissue disorder—Vemurafenib—skin cancer	0.00525	0.00525	CcSEcCtD
Deferoxamine—Neuropathy—Temozolomide—skin cancer	0.0051	0.0051	CcSEcCtD
Deferoxamine—Infestation NOS—Imiquimod—skin cancer	0.00507	0.00507	CcSEcCtD
Deferoxamine—Infestation—Imiquimod—skin cancer	0.00507	0.00507	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Vismodegib—skin cancer	0.00502	0.00502	CcSEcCtD
Deferoxamine—Eye disorder—Vemurafenib—skin cancer	0.00499	0.00499	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Imiquimod—skin cancer	0.00497	0.00497	CcSEcCtD
Deferoxamine—Abdominal pain—Vismodegib—skin cancer	0.00486	0.00486	CcSEcCtD
Deferoxamine—Angiopathy—Vemurafenib—skin cancer	0.00485	0.00485	CcSEcCtD
Deferoxamine—Mediastinal disorder—Vemurafenib—skin cancer	0.00481	0.00481	CcSEcCtD
Deferoxamine—Scotoma—Docetaxel—skin cancer	0.00476	0.00476	CcSEcCtD
Deferoxamine—Erythema—Vemurafenib—skin cancer	0.00465	0.00465	CcSEcCtD
Deferoxamine—Urinary tract disorder—Imiquimod—skin cancer	0.0045	0.0045	CcSEcCtD
Deferoxamine—Connective tissue disorder—Imiquimod—skin cancer	0.00448	0.00448	CcSEcCtD
Deferoxamine—Urethral disorder—Imiquimod—skin cancer	0.00446	0.00446	CcSEcCtD
Deferoxamine—Visual impairment—Imiquimod—skin cancer	0.00439	0.00439	CcSEcCtD
Deferoxamine—Pruritus—Vismodegib—skin cancer	0.00435	0.00435	CcSEcCtD
Deferoxamine—Eye disorder—Imiquimod—skin cancer	0.00426	0.00426	CcSEcCtD
Deferoxamine—Tinnitus—Imiquimod—skin cancer	0.00425	0.00425	CcSEcCtD
Deferoxamine—Diarrhoea—Vismodegib—skin cancer	0.0042	0.0042	CcSEcCtD
Deferoxamine—Angiopathy—Imiquimod—skin cancer	0.00413	0.00413	CcSEcCtD
Deferoxamine—Swelling—Fluorouracil—skin cancer	0.00412	0.00412	CcSEcCtD
Deferoxamine—Immune system disorder—Imiquimod—skin cancer	0.00411	0.00411	CcSEcCtD
Deferoxamine—Mediastinal disorder—Imiquimod—skin cancer	0.0041	0.0041	CcSEcCtD
Deferoxamine—Arrhythmia—Imiquimod—skin cancer	0.00407	0.00407	CcSEcCtD
Deferoxamine—Bone disorder—Docetaxel—skin cancer	0.004	0.004	CcSEcCtD
Deferoxamine—Erythema—Imiquimod—skin cancer	0.00396	0.00396	CcSEcCtD
Deferoxamine—Myalgia—Vemurafenib—skin cancer	0.00396	0.00396	CcSEcCtD
Deferoxamine—Arthralgia—Vemurafenib—skin cancer	0.00396	0.00396	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00393	0.00393	CcSEcCtD
Deferoxamine—Vomiting—Vismodegib—skin cancer	0.00391	0.00391	CcSEcCtD
Deferoxamine—Anaphylactic shock—Vemurafenib—skin cancer	0.00379	0.00379	CcSEcCtD
Deferoxamine—Bone pain—Docetaxel—skin cancer	0.00377	0.00377	CcSEcCtD
Deferoxamine—Infection—Vemurafenib—skin cancer	0.00377	0.00377	CcSEcCtD
Deferoxamine—Nervous system disorder—Vemurafenib—skin cancer	0.00372	0.00372	CcSEcCtD
Deferoxamine—Skin disorder—Vemurafenib—skin cancer	0.00369	0.00369	CcSEcCtD
Deferoxamine—Nausea—Vismodegib—skin cancer	0.00365	0.00365	CcSEcCtD
Deferoxamine—Angioedema—Imiquimod—skin cancer	0.00362	0.00362	CcSEcCtD
Deferoxamine—Injection site reaction—Docetaxel—skin cancer	0.00359	0.00359	CcSEcCtD
Deferoxamine—Hypotension—Vemurafenib—skin cancer	0.00355	0.00355	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00346	0.00346	CcSEcCtD
Deferoxamine—Convulsion—Imiquimod—skin cancer	0.00344	0.00344	CcSEcCtD
Deferoxamine—Neuropathy—Docetaxel—skin cancer	0.00339	0.00339	CcSEcCtD
Deferoxamine—Myalgia—Imiquimod—skin cancer	0.00338	0.00338	CcSEcCtD
Deferoxamine—Arthralgia—Imiquimod—skin cancer	0.00338	0.00338	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00335	0.00335	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00328	0.00328	CcSEcCtD
Deferoxamine—Oedema—Imiquimod—skin cancer	0.00324	0.00324	CcSEcCtD
Deferoxamine—Infection—Imiquimod—skin cancer	0.00321	0.00321	CcSEcCtD
Deferoxamine—Dysuria—Temozolomide—skin cancer	0.00319	0.00319	CcSEcCtD
Deferoxamine—Shock—Imiquimod—skin cancer	0.00318	0.00318	CcSEcCtD
Deferoxamine—Nervous system disorder—Imiquimod—skin cancer	0.00317	0.00317	CcSEcCtD
Deferoxamine—Tachycardia—Imiquimod—skin cancer	0.00316	0.00316	CcSEcCtD
Deferoxamine—Skin disorder—Imiquimod—skin cancer	0.00314	0.00314	CcSEcCtD
Deferoxamine—Eosinophilia—Fluorouracil—skin cancer	0.00311	0.00311	CcSEcCtD
Deferoxamine—Infestation NOS—Temozolomide—skin cancer	0.00304	0.00304	CcSEcCtD
Deferoxamine—Infestation—Temozolomide—skin cancer	0.00304	0.00304	CcSEcCtD
Deferoxamine—Body temperature increased—Vemurafenib—skin cancer	0.003	0.003	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Temozolomide—skin cancer	0.00298	0.00298	CcSEcCtD
Deferoxamine—Swelling—Docetaxel—skin cancer	0.00297	0.00297	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00295	0.00295	CcSEcCtD
Deferoxamine—Paraesthesia—Imiquimod—skin cancer	0.00291	0.00291	CcSEcCtD
Deferoxamine—Dyspnoea—Imiquimod—skin cancer	0.00288	0.00288	CcSEcCtD
Deferoxamine—Erythema—Bleomycin—skin cancer	0.00282	0.00282	CcSEcCtD
Deferoxamine—Infestation NOS—Fluorouracil—skin cancer	0.0028	0.0028	CcSEcCtD
Deferoxamine—Infestation—Fluorouracil—skin cancer	0.0028	0.0028	CcSEcCtD
Deferoxamine—Hypersensitivity—Vemurafenib—skin cancer	0.0028	0.0028	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00279	0.00279	CcSEcCtD
Deferoxamine—Visual disturbance—Docetaxel—skin cancer	0.00277	0.00277	CcSEcCtD
Deferoxamine—Pain—Imiquimod—skin cancer	0.00277	0.00277	CcSEcCtD
Deferoxamine—Renal impairment—Docetaxel—skin cancer	0.00276	0.00276	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Fluorouracil—skin cancer	0.00275	0.00275	CcSEcCtD
Deferoxamine—Hallucination—Temozolomide—skin cancer	0.00272	0.00272	CcSEcCtD
Deferoxamine—Urinary tract disorder—Temozolomide—skin cancer	0.0027	0.0027	CcSEcCtD
Deferoxamine—Pruritus—Vemurafenib—skin cancer	0.00268	0.00268	CcSEcCtD
Deferoxamine—Connective tissue disorder—Temozolomide—skin cancer	0.00268	0.00268	CcSEcCtD
Deferoxamine—Urethral disorder—Temozolomide—skin cancer	0.00268	0.00268	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Imiquimod—skin cancer	0.00265	0.00265	CcSEcCtD
Deferoxamine—Visual impairment—Temozolomide—skin cancer	0.00263	0.00263	CcSEcCtD
Deferoxamine—Erythema—Dactinomycin—skin cancer	0.00263	0.00263	CcSEcCtD
Deferoxamine—Diarrhoea—Vemurafenib—skin cancer	0.0026	0.0026	CcSEcCtD
Deferoxamine—Urticaria—Imiquimod—skin cancer	0.00257	0.00257	CcSEcCtD
Deferoxamine—Abdominal pain—Imiquimod—skin cancer	0.00256	0.00256	CcSEcCtD
Deferoxamine—Body temperature increased—Imiquimod—skin cancer	0.00256	0.00256	CcSEcCtD
Deferoxamine—Eye disorder—Temozolomide—skin cancer	0.00255	0.00255	CcSEcCtD
Deferoxamine—Tinnitus—Temozolomide—skin cancer	0.00254	0.00254	CcSEcCtD
Deferoxamine—Leukopenia—Bleomycin—skin cancer	0.00252	0.00252	CcSEcCtD
Deferoxamine—Dizziness—Vemurafenib—skin cancer	0.00251	0.00251	CcSEcCtD
Deferoxamine—Angiopathy—Temozolomide—skin cancer	0.00248	0.00248	CcSEcCtD
Deferoxamine—Immune system disorder—Temozolomide—skin cancer	0.00247	0.00247	CcSEcCtD
Deferoxamine—Mediastinal disorder—Temozolomide—skin cancer	0.00246	0.00246	CcSEcCtD
Deferoxamine—Vomiting—Vemurafenib—skin cancer	0.00241	0.00241	CcSEcCtD
Deferoxamine—Myalgia—Bleomycin—skin cancer	0.0024	0.0024	CcSEcCtD
Deferoxamine—Hypersensitivity—Imiquimod—skin cancer	0.00238	0.00238	CcSEcCtD
Deferoxamine—Headache—Vemurafenib—skin cancer	0.00238	0.00238	CcSEcCtD
Deferoxamine—Erythema—Temozolomide—skin cancer	0.00238	0.00238	CcSEcCtD
Deferoxamine—Leukopenia—Dactinomycin—skin cancer	0.00235	0.00235	CcSEcCtD
Deferoxamine—Oedema—Bleomycin—skin cancer	0.0023	0.0023	CcSEcCtD
Deferoxamine—Anaphylactic shock—Bleomycin—skin cancer	0.0023	0.0023	CcSEcCtD
Deferoxamine—Pruritus—Imiquimod—skin cancer	0.00229	0.00229	CcSEcCtD
Deferoxamine—Infection—Bleomycin—skin cancer	0.00228	0.00228	CcSEcCtD
Deferoxamine—Nausea—Vemurafenib—skin cancer	0.00225	0.00225	CcSEcCtD
Deferoxamine—Thrombocytopenia—Bleomycin—skin cancer	0.00225	0.00225	CcSEcCtD
Deferoxamine—Arrhythmia—Fluorouracil—skin cancer	0.00225	0.00225	CcSEcCtD
Deferoxamine—Vision blurred—Temozolomide—skin cancer	0.00224	0.00224	CcSEcCtD
Deferoxamine—Myalgia—Dactinomycin—skin cancer	0.00224	0.00224	CcSEcCtD
Deferoxamine—Diarrhoea—Imiquimod—skin cancer	0.00221	0.00221	CcSEcCtD
Deferoxamine—Erythema—Fluorouracil—skin cancer	0.00219	0.00219	CcSEcCtD
Deferoxamine—Angioedema—Temozolomide—skin cancer	0.00217	0.00217	CcSEcCtD
Deferoxamine—Hypotension—Bleomycin—skin cancer	0.00215	0.00215	CcSEcCtD
Deferoxamine—Oedema—Dactinomycin—skin cancer	0.00214	0.00214	CcSEcCtD
Deferoxamine—Dizziness—Imiquimod—skin cancer	0.00214	0.00214	CcSEcCtD
Deferoxamine—Infection—Dactinomycin—skin cancer	0.00213	0.00213	CcSEcCtD
Deferoxamine—Leukopenia—Temozolomide—skin cancer	0.00213	0.00213	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dactinomycin—skin cancer	0.0021	0.0021	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00209	0.00209	CcSEcCtD
Deferoxamine—Paraesthesia—Bleomycin—skin cancer	0.00206	0.00206	CcSEcCtD
Deferoxamine—Vision blurred—Fluorouracil—skin cancer	0.00206	0.00206	CcSEcCtD
Deferoxamine—Convulsion—Temozolomide—skin cancer	0.00206	0.00206	CcSEcCtD
Deferoxamine—Vomiting—Imiquimod—skin cancer	0.00206	0.00206	CcSEcCtD
Deferoxamine—Dyspnoea—Bleomycin—skin cancer	0.00205	0.00205	CcSEcCtD
Deferoxamine—Headache—Imiquimod—skin cancer	0.00203	0.00203	CcSEcCtD
Deferoxamine—Arthralgia—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Deferoxamine—Myalgia—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Deferoxamine—Infestation NOS—Docetaxel—skin cancer	0.00202	0.00202	CcSEcCtD
Deferoxamine—Infestation—Docetaxel—skin cancer	0.00202	0.00202	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00201	0.00201	CcSEcCtD
Deferoxamine—Renal failure—Docetaxel—skin cancer	0.00199	0.00199	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Docetaxel—skin cancer	0.00198	0.00198	CcSEcCtD
Deferoxamine—Pain—Bleomycin—skin cancer	0.00197	0.00197	CcSEcCtD
Deferoxamine—Leukopenia—Fluorouracil—skin cancer	0.00196	0.00196	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00195	0.00195	CcSEcCtD
Deferoxamine—Anaphylactic shock—Temozolomide—skin cancer	0.00194	0.00194	CcSEcCtD
Deferoxamine—Oedema—Temozolomide—skin cancer	0.00194	0.00194	CcSEcCtD
Deferoxamine—Infection—Temozolomide—skin cancer	0.00193	0.00193	CcSEcCtD
Deferoxamine—Nausea—Imiquimod—skin cancer	0.00192	0.00192	CcSEcCtD
Deferoxamine—Nervous system disorder—Temozolomide—skin cancer	0.0019	0.0019	CcSEcCtD
Deferoxamine—Thrombocytopenia—Temozolomide—skin cancer	0.0019	0.0019	CcSEcCtD
Deferoxamine—Convulsion—Fluorouracil—skin cancer	0.0019	0.0019	CcSEcCtD
Deferoxamine—Skin disorder—Temozolomide—skin cancer	0.00188	0.00188	CcSEcCtD
Deferoxamine—Myalgia—Fluorouracil—skin cancer	0.00186	0.00186	CcSEcCtD
Deferoxamine—Pain—Dactinomycin—skin cancer	0.00183	0.00183	CcSEcCtD
Deferoxamine—Urticaria—Bleomycin—skin cancer	0.00183	0.00183	CcSEcCtD
Deferoxamine—Body temperature increased—Bleomycin—skin cancer	0.00182	0.00182	CcSEcCtD
Deferoxamine—Urinary tract disorder—Docetaxel—skin cancer	0.00179	0.00179	CcSEcCtD
Deferoxamine—Anaphylactic shock—Fluorouracil—skin cancer	0.00179	0.00179	CcSEcCtD
Deferoxamine—Oedema—Fluorouracil—skin cancer	0.00179	0.00179	CcSEcCtD
Deferoxamine—Connective tissue disorder—Docetaxel—skin cancer	0.00178	0.00178	CcSEcCtD
Deferoxamine—Urethral disorder—Docetaxel—skin cancer	0.00178	0.00178	CcSEcCtD
Deferoxamine—Infection—Fluorouracil—skin cancer	0.00178	0.00178	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00177	0.00177	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00175	0.00175	CcSEcCtD
Deferoxamine—Nervous system disorder—Fluorouracil—skin cancer	0.00175	0.00175	CcSEcCtD
Deferoxamine—Thrombocytopenia—Fluorouracil—skin cancer	0.00175	0.00175	CcSEcCtD
Deferoxamine—Visual impairment—Docetaxel—skin cancer	0.00175	0.00175	CcSEcCtD
Deferoxamine—Tachycardia—Fluorouracil—skin cancer	0.00174	0.00174	CcSEcCtD
Deferoxamine—Paraesthesia—Temozolomide—skin cancer	0.00174	0.00174	CcSEcCtD
Deferoxamine—Dyspnoea—Temozolomide—skin cancer	0.00173	0.00173	CcSEcCtD
Deferoxamine—Eye disorder—Docetaxel—skin cancer	0.0017	0.0017	CcSEcCtD
Deferoxamine—Abdominal pain—Dactinomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Deferoxamine—Body temperature increased—Dactinomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Deferoxamine—Hypersensitivity—Bleomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00167	0.00167	CcSEcCtD
Deferoxamine—Hypotension—Fluorouracil—skin cancer	0.00167	0.00167	CcSEcCtD
Deferoxamine—Pain—Temozolomide—skin cancer	0.00166	0.00166	CcSEcCtD
Deferoxamine—Angiopathy—Docetaxel—skin cancer	0.00165	0.00165	CcSEcCtD
Deferoxamine—Immune system disorder—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Deferoxamine—Mediastinal disorder—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00163	0.00163	CcSEcCtD
Deferoxamine—Pruritus—Bleomycin—skin cancer	0.00163	0.00163	CcSEcCtD
Deferoxamine—Arrhythmia—Docetaxel—skin cancer	0.00162	0.00162	CcSEcCtD
Deferoxamine—Paraesthesia—Fluorouracil—skin cancer	0.0016	0.0016	CcSEcCtD
Deferoxamine—Dyspnoea—Fluorouracil—skin cancer	0.00159	0.00159	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Temozolomide—skin cancer	0.00159	0.00159	CcSEcCtD
Deferoxamine—Erythema—Docetaxel—skin cancer	0.00158	0.00158	CcSEcCtD
Deferoxamine—Hypersensitivity—Dactinomycin—skin cancer	0.00158	0.00158	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00154	0.00154	CcSEcCtD
Deferoxamine—Urticaria—Temozolomide—skin cancer	0.00154	0.00154	CcSEcCtD
Deferoxamine—Abdominal pain—Temozolomide—skin cancer	0.00153	0.00153	CcSEcCtD
Deferoxamine—Body temperature increased—Temozolomide—skin cancer	0.00153	0.00153	CcSEcCtD
Deferoxamine—Pain—Fluorouracil—skin cancer	0.00153	0.00153	CcSEcCtD
Deferoxamine—Muscle spasms—Docetaxel—skin cancer	0.00152	0.00152	CcSEcCtD
Deferoxamine—Diarrhoea—Dactinomycin—skin cancer	0.00147	0.00147	CcSEcCtD
Deferoxamine—Vomiting—Bleomycin—skin cancer	0.00146	0.00146	CcSEcCtD
Deferoxamine—Hypersensitivity—Temozolomide—skin cancer	0.00143	0.00143	CcSEcCtD
Deferoxamine—Urticaria—Fluorouracil—skin cancer	0.00142	0.00142	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Deferoxamine—Body temperature increased—Fluorouracil—skin cancer	0.00141	0.00141	CcSEcCtD
Deferoxamine—Pruritus—Temozolomide—skin cancer	0.00137	0.00137	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—skin cancer	0.00137	0.00137	CcSEcCtD
Deferoxamine—Nausea—Bleomycin—skin cancer	0.00137	0.00137	CcSEcCtD
Deferoxamine—Vomiting—Dactinomycin—skin cancer	0.00136	0.00136	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—skin cancer	0.00135	0.00135	CcSEcCtD
Deferoxamine—Myalgia—Docetaxel—skin cancer	0.00135	0.00135	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Deferoxamine—Diarrhoea—Temozolomide—skin cancer	0.00133	0.00133	CcSEcCtD
Deferoxamine—Hypersensitivity—Fluorouracil—skin cancer	0.00132	0.00132	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—skin cancer	0.00129	0.00129	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—skin cancer	0.00129	0.00129	CcSEcCtD
Deferoxamine—Dizziness—Temozolomide—skin cancer	0.00128	0.00128	CcSEcCtD
Deferoxamine—Infection—Docetaxel—skin cancer	0.00128	0.00128	CcSEcCtD
Deferoxamine—Nausea—Dactinomycin—skin cancer	0.00127	0.00127	CcSEcCtD
Deferoxamine—Shock—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—skin cancer	0.00126	0.00126	CcSEcCtD
Deferoxamine—Pruritus—Fluorouracil—skin cancer	0.00126	0.00126	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—skin cancer	0.00126	0.00126	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—skin cancer	0.00126	0.00126	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—skin cancer	0.00125	0.00125	CcSEcCtD
Deferoxamine—Vomiting—Temozolomide—skin cancer	0.00123	0.00123	CcSEcCtD
Deferoxamine—Diarrhoea—Fluorouracil—skin cancer	0.00122	0.00122	CcSEcCtD
Deferoxamine—Headache—Temozolomide—skin cancer	0.00121	0.00121	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—skin cancer	0.00121	0.00121	CcSEcCtD
Deferoxamine—Dizziness—Fluorouracil—skin cancer	0.00118	0.00118	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00117	0.00117	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—skin cancer	0.00116	0.00116	CcSEcCtD
Deferoxamine—Nausea—Temozolomide—skin cancer	0.00115	0.00115	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—skin cancer	0.00115	0.00115	CcSEcCtD
Deferoxamine—Vomiting—Fluorouracil—skin cancer	0.00114	0.00114	CcSEcCtD
Deferoxamine—Headache—Fluorouracil—skin cancer	0.00112	0.00112	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00111	0.00111	CcSEcCtD
Deferoxamine—Pain—Docetaxel—skin cancer	0.0011	0.0011	CcSEcCtD
Deferoxamine—Nausea—Fluorouracil—skin cancer	0.00106	0.00106	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—skin cancer	0.00105	0.00105	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—skin cancer	0.00102	0.00102	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—skin cancer	0.00102	0.00102	CcSEcCtD
Deferoxamine—Hypersensitivity—Docetaxel—skin cancer	0.00095	0.00095	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—skin cancer	0.000912	0.000912	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—skin cancer	0.000882	0.000882	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—skin cancer	0.000853	0.000853	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—skin cancer	0.00082	0.00082	CcSEcCtD
Deferoxamine—Headache—Docetaxel—skin cancer	0.000808	0.000808	CcSEcCtD
Deferoxamine—Nausea—Docetaxel—skin cancer	0.000766	0.000766	CcSEcCtD
